Back to Atlas
CTransientStandard research/education caution
CMP-0366
Experimental
KPV
Anti-inflammatory
GI, skin and inflammation support positioning
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Peptide
- Primary mechanism
- Alpha-MSH fragment/inflammatory signaling
- Primary market use
- Inflammation/GI
Pharmacology
- Molecular weight (Da)
- 372.5
- Oral bioavailability
- Low/unknown
- Half-life
- Short; not established
- Route tags
- Topical; oral/other route-dependent
- Evidence level
- Preclinical
- Clinical status
- Experimental
- Value-for-money score
- 5 / 10
Reported protocol signal
Oral: • 500 mcg capsule twice a day (Metabolic Optimization Guide) SQ: • 200-400 daily (World of Peptides) Topical: • KPV (2 mg/g) + D3 (1000 iu/g) topical cream (30 ml TopiClick): 0.5 ml applied to area twice daily
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Requires continued anti-inflammatory signaling